- Home
- ZIONO vs TNGX Comparison
ZIONO vs TNGX Comparison
Compare ZIONO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIONO
- TNGX
- Stock Information
- Founded
- ZIONO N/A
- TNGX 2014
- Country
- ZIONO United States
- TNGX United States
- Employees
- ZIONO 9679
- TNGX N/A
- Industry
- ZIONO Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ZIONO Finance
- TNGX Health Care
- Exchange
- ZIONO Nasdaq
- TNGX Nasdaq
- Market Cap
- ZIONO N/A
- TNGX 735.0M
- IPO Year
- ZIONO N/A
- TNGX N/A
- Fundamental
- Price
- ZIONO $26.39
- TNGX $6.64
- Analyst Decision
- ZIONO
- TNGX Strong Buy
- Analyst Count
- ZIONO 0
- TNGX 8
- Target Price
- ZIONO N/A
- TNGX $15.14
- AVG Volume (30 Days)
- ZIONO N/A
- TNGX 885.7K
- Earning Date
- ZIONO N/A
- TNGX 11-06-2024
- Dividend Yield
- ZIONO N/A
- TNGX N/A
- EPS Growth
- ZIONO N/A
- TNGX N/A
- EPS
- ZIONO N/A
- TNGX N/A
- Revenue
- ZIONO N/A
- TNGX $42,509,000.00
- Revenue This Year
- ZIONO N/A
- TNGX $18.15
- Revenue Next Year
- ZIONO N/A
- TNGX N/A
- P/E Ratio
- ZIONO N/A
- TNGX N/A
- Revenue Growth
- ZIONO N/A
- TNGX 26.16
- 52 Week Low
- ZIONO N/A
- TNGX $6.33
- 52 Week High
- ZIONO N/A
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- ZIONO 52.08
- TNGX 37.15
- Support Level
- ZIONO $26.71
- TNGX $6.83
- Resistance Level
- ZIONO $27.01
- TNGX $7.47
- Average True Range (ATR)
- ZIONO 0.19
- TNGX 0.37
- MACD
- ZIONO -0.03
- TNGX 0.11
- Stochastic Oscillator
- ZIONO 21.25
- TNGX 27.31
About ZIONO Zions Bancorporation N.A. Dep Shs Repstg 1/40th Perp Pfd Ser G
Zions Bancorporation is a regional U.S. bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions primarily focuses on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.